Middle East & Africa Injectable Drug Delivery Market, 2020 – ResearchAndMarkets.com

July 28, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Middle East and Africa Injectable Drug Delivery Market 2019-2027” report has been added to ResearchAndMarkets.com’s offering.


The publisher’s report on the injectable drug delivery market in the Middle East and Africa estimates the industry to grow at a CAGR of 11.04% during the forecast period 2019-2027.

Turkey, the United Arab Emirates, Saudi Arabia and the Rest of the Middle East & Africa are the countries studied in the Middle East & Africa injectable drug delivery market.

The increasing chronic diseases, technological developments in drug technology and the growing pharmaceutical industry are the key factors driving the market growth in the Middle East and Africa. There is a steady increase in the elderly population in Middle Eastern countries like Saudi Arabia and Turkey. The rising geriatric population, along with the increasing prevalence of cardiovascular diseases, is driving the market growth in these countries.

With the health awareness programs on HIV and TB being conducted successfully, there is a decline in the mortality rate in South Africa and thereby increasing the life expectancy. According to the World Health Organization (WHO), there is an increase in cancer patients in the country. If no action is taken, these numbers are expected to rise further and will probably lead to the market growth of injectable drug delivery.

The increasing occurrence of AIDS, Alzheimer’s and arthritis have led to the demand for new bioactive elements in Rest of the Middle East & Africa. This factor has increased the demand for injectable drug delivery technology in this region. Several strategic initiatives have been planned in the region to encourage emerging technology. (Read more…)

Key Topics Covered:

1. Middle East and Africa Injectable Drug Delivery Market – Summary

2. Industry Outlook

2.1. Market Definitions

2.2. Porter’s Five Forces Model

2.2.1. Threat of New Entrant

2.2.2. Threat of Substitute

2.2.3. Bargaining Power of Buyers

2.2.4. Bargaining Power of Suppliers

2.2.5. Intensity of Competitive Rivalry

2.3. Market Share Outlook

2.4. Key Insight

2.5. Key Buying Criteria

2.6. Legal Requirement

2.7. Market Attractiveness Index

2.8. Market Drivers

2.8.1. Increasing Geriatric Population

2.8.2. Technological Advancement

2.8.3. Growing Occurrence of Autoimmune Diseases

2.9. Market Restraint

2.9.1. High Manufacturing Cost of the Injectable Drug Delivery

2.10. Market Opportunity

2.10.1. Development of Better Injectable Systems

2.11. Market Challenges

2.11.1. Developments in the Alternate Drug Delivery System

2.11.2. Stringent Regulations

3. Injectable Drug Delivery Market Outlook – by Device Type

3.1. Pen Injector

3.2. AutoInjector

3.3. Needle-Free Injector

3.4. Prefilled Syringe

4. Injectable Drug Delivery Market Outlook – by Route of Administration

4.1. Subcutaneous

4.2. Intramuscular

4.3. Intravenous (Iv)

4.4. Other Route of Administration

5. Injectable Drug Delivery Market Outlook – by End-User

5.1. Clinics/ Physician Offices

5.2. Ambulatory Care

5.3. Hospital

5.4. Home Based

5.5. Others End-User

6. Injectable Drug Delivery Market – Middle East and Africa

6.1. Country Analysis

6.1.1. Saudi Arabia

6.1.2. Turkey

6.1.3. United Arab Emirates

6.1.4. South Africa

6.1.5. Rest of Middle East & Africa

7. Company Profiles

7.1. Baxter

7.2. Becton, Dickinson and Company (BD)

7.3. Elcam Medical

7.4. Eli Lilly and Company

7.5. Gerresheimer

7.6. Injex

7.7. Novartis AG

7.8. Novo Nordisk A/S

7.9. Pfizer Inc

7.10. Sanofi

7.11. Schott AG

7.12. Terumo Corporation

7.13. Teva Pharmaceutical Industries Ltd

7.14. West Pharmaceutical Services Inc

7.15. Ypsomed

8. Research Methodology & Scope

8.1. Research Scope & Deliverables

8.1.1. Objectives of Study

8.1.2. Scope of Study

8.2. Sources of Data

8.2.1. Primary Data Sources

8.2.2. Secondary Data Sources

8.3. Research Methodology

8.3.1. Evaluation of Proposed Market

8.3.2. Identification of Data Sources

8.3.3. Assessment of Market Determinants

8.3.4. Data Collection

8.3.5. Data Validation & Analysis

For more information about this report visit https://www.researchandmarkets.com/r/syd4ub



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900